AMGN vs. IDXX: A Head-to-Head Stock Comparison

Updated on October 6, 2025

Here’s a clear look at AMGN and IDXX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	AMGN	IDXX
Company Name	Amgen Inc.	IDEXX Laboratories, Inc.
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Health Care Equipment & Supplies
Market Capitalization	160.37 billion USD	50.50 billion USD
Exchange	NasdaqGS	NasdaqGS
Listing Date	June 17, 1983	June 21, 1991
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of AMGN and IDXX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

AMGN vs. IDXX: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	AMGN	IDXX
5-Day Price Return	8.73%	0.10%
13-Week Price Return	-0.12%	15.39%
26-Week Price Return	-4.38%	50.30%
52-Week Price Return	-6.83%	29.88%
Month-to-Date Return	5.56%	-1.21%
Year-to-Date Return	14.29%	52.67%
10-Day Avg. Volume	2.71M	0.40M
3-Month Avg. Volume	2.44M	0.53M
3-Month Volatility	26.15%	61.46%
Beta	0.46	1.70

Profitability

Return on Equity (TTM)

AMGN

97.92%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, AMGN’s Return on Equity of 97.92% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

IDXX

64.42%

Health Care Equipment & Supplies Industry

Max: 29.93%
Q3: 16.99%
Median: 9.28%
Q1: 5.10%
Min: -12.52%

IDXX’s Return on Equity of 64.42% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

AMGN vs. IDXX: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Net Profit Margin (TTM)

AMGN

18.96%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

AMGN’s Net Profit Margin of 18.96% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

IDXX

24.41%

Health Care Equipment & Supplies Industry

Max: 24.41%
Q3: 13.71%
Median: 10.08%
Q1: 5.96%
Min: -5.58%

A Net Profit Margin of 24.41% places IDXX in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.

AMGN vs. IDXX: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Operating Profit Margin (TTM)

AMGN

24.01%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

An Operating Profit Margin of 24.01% places AMGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

IDXX

31.09%

Health Care Equipment & Supplies Industry

Max: 31.09%
Q3: 18.11%
Median: 15.07%
Q1: 8.48%
Min: -0.28%

An Operating Profit Margin of 31.09% places IDXX in the upper quartile for the Health Care Equipment & Supplies industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

AMGN vs. IDXX: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Profitability at a Glance

Symbol	AMGN	IDXX
Return on Equity (TTM)	97.92%	64.42%
Return on Assets (TTM)	7.35%	29.89%
Net Profit Margin (TTM)	18.96%	24.41%
Operating Profit Margin (TTM)	24.01%	31.09%
Gross Profit Margin (TTM)	69.71%	61.54%

Financial Strength

Current Ratio (MRQ)

AMGN

1.31

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

AMGN’s Current Ratio of 1.31 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

IDXX

1.11

Health Care Equipment & Supplies Industry

Max: 5.19
Q3: 3.00
Median: 2.13
Q1: 1.44
Min: 0.86

IDXX’s Current Ratio of 1.11 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

AMGN vs. IDXX: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Debt-to-Equity Ratio (MRQ)

AMGN

7.57

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 7.57, AMGN operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

IDXX

0.76

Health Care Equipment & Supplies Industry

Max: 1.61
Q3: 0.76
Median: 0.45
Q1: 0.14
Min: 0.00

IDXX’s Debt-to-Equity Ratio of 0.76 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

AMGN vs. IDXX: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Interest Coverage Ratio (TTM)

AMGN

2.40

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

AMGN’s Interest Coverage Ratio of 2.40 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

IDXX

49.24

Health Care Equipment & Supplies Industry

Max: 56.35
Q3: 25.56
Median: 9.60
Q1: 3.78
Min: -26.49

IDXX’s Interest Coverage Ratio of 49.24 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

AMGN vs. IDXX: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Financial Strength at a Glance

Symbol	AMGN	IDXX
Current Ratio (MRQ)	1.31	1.11
Quick Ratio (MRQ)	0.98	0.75
Debt-to-Equity Ratio (MRQ)	7.57	0.76
Interest Coverage Ratio (TTM)	2.40	49.24

Growth

Revenue Growth

AMGN vs. IDXX: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

AMGN vs. IDXX: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

AMGN

3.06%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AMGN’s Dividend Yield of 3.06% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 4.15%
Q3: 1.76%
Median: 0.79%
Q1: 0.00%
Min: 0.00%

IDXX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

AMGN vs. IDXX: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend Payout Ratio (TTM)

AMGN

82.64%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 82.64%, AMGN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

IDXX

0.00%

Health Care Equipment & Supplies Industry

Max: 160.00%
Q3: 66.60%
Median: 27.49%
Q1: 0.00%
Min: 0.00%

IDXX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

AMGN vs. IDXX: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Dividend at a Glance

Symbol	AMGN	IDXX
Dividend Yield (TTM)	3.06%	0.00%
Dividend Payout Ratio (TTM)	82.64%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

AMGN

24.19

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

AMGN’s P/E Ratio of 24.19 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

IDXX

51.18

Health Care Equipment & Supplies Industry

Max: 67.29
Q3: 47.01
Median: 30.94
Q1: 23.91
Min: 10.79

A P/E Ratio of 51.18 places IDXX in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

AMGN vs. IDXX: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Sales Ratio (TTM)

AMGN

4.59

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

AMGN’s P/S Ratio of 4.59 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

IDXX

12.49

Health Care Equipment & Supplies Industry

Max: 9.49
Q3: 5.41
Median: 2.86
Q1: 2.07
Min: 0.74

With a P/S Ratio of 12.49, IDXX trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

AMGN vs. IDXX: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Price-to-Book Ratio (MRQ)

AMGN

20.21

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

AMGN’s P/B Ratio of 20.21 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

IDXX

29.57

Health Care Equipment & Supplies Industry

Max: 10.85
Q3: 6.56
Median: 3.53
Q1: 2.36
Min: 0.71

At 29.57, IDXX’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

AMGN vs. IDXX: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Health Care Equipment & Supplies industry benchmarks.

Valuation at a Glance

Symbol	AMGN	IDXX
Price-to-Earnings Ratio (TTM)	24.19	51.18
Price-to-Sales Ratio (TTM)	4.59	12.49
Price-to-Book Ratio (MRQ)	20.21	29.57
Price-to-Free Cash Flow Ratio (TTM)	14.59	65.14